Current partner codePEPTIDESDE
PeptideStat
Menu

Vendors

Compare pricesVendor directoryVendor reviewsDiscount codesLab tests & COAs

Research

ResearchDatabaseClinical trials

Tools

All calculatorsReconstitutionAccumulationUnit converterPeptide chemistry
NCT05965908·Phase 3·INTERVENTIONAL

Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome

LiraglutideOtherCompleted

Status

Completed

Phase

Phase 3

Enrollment

150

Locations

1

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

The aim of this study is to compare the hormonal, metabolic and clinical effects of metformin and liraglutide in infertile women with PCOs.

Full detailed description

It is a Prospective randomized controlled trial .The study will include 80 randomly selected infertile women aged between 18 and 45 years, from Gynecology and obstetrics department Beni-Suef University Hospital whom diagnosed with polycystic ovarian syndrome (PCOS), The study will include two groups; each group consists of 40 patients:- * Group1 (n=50) will be treated by liraglutide monotherapy. * Group 2 (n=50) will be treated by metformin monotherapy. * Group 3 (n=50) will be a control group. To assess the metabolic effect of each treatment, the following parameters will be assessed before and after the treatment * To assess the hormonal effect of each treatment, the following tests will be assessed before and after treatment * Total Testosterone (TT) * Dehydroepiandrosterone (DHEA) To assess the clinical effect of the drugs, the following will be assessed before and after treatment: The ovulation was assessed on the tenth or eleventh day of menstruation. The chemical and clinical pregnancy rates were evaluated

Interventions

Treatment arms and agents.

DRUG

liraglutide

glucagon-like peptide 1 receptor agonist

DRUG

Metformin

biguanide antihyperglycemic

Timeline

From registration to results.

  1. First posted

    Jul 28, 2023

  2. Study start

    Jan 30, 2024

  3. Primary completion

    Mar 30, 2025

  4. Study completion

    Mar 30, 2025

  5. Results posted

    Not reported

  6. Registry updated

    Mar 6, 2026

Outcomes

What the study measures.

Primary outcomes

Body weight loss

Time frame · 1 months

basal body weight - body weight reached after treatment

Secondary outcomes

Not reported in the indexed record.

Eligibility

Who can take part.

Minimum age
20 Years
Maximum age
40 Years
Sex
FEMALE
Healthy volunteers
No

Inclusion Criteria: * aged between 20 and 45 years * PCO Exclusion Criteria: 1. congenital adrenal hyperplasia 2. poorly controlled thyroid disease 3. Taking antidiabetic drugs which can affect insulin resistance 4. chronic kidney disease and history of recurrent urinary tract infections 5. liver dysfunction 6. documented use of oral hormonal contraceptives and hormone-releasing implants

Study locations

1 registered sites.

Egypt. Showing up to 24 locations stored in the fast local snapshot.

Beni-suef university Hospital

Banī Suwayf, Beni Suweif Governorate, Egypt

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

ClinicalTrials.gov ↗Search PubMed ↗Search FDA ↗Search EMA ↗

Related trials

More studies on Liraglutide.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.

TrialsLiraglutide trial dashboard →DatabaseLiraglutide database entry →ResearchLiraglutide research guide →